Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2010

View Archived Issues

Trius Therapeutics develops new antimicrobials targeting dihydrofolate reductase

OC-000459 inhibits late-phase airway response after allergen challenge in patients with asthma

Tiotropium/olodaterol combination more effective than tiotropium in COPD

Scientists explore antibacterial potential of GE-2270 analogues

BiondVax begins phase IIa trial of Multimeric-001 universal flu vaccine

BioLineRx acquires rights to Santhera's melanocortin MC4 receptor antagonists for cachexia

CyDex Pharma obtains rights to Captisol-enabled intravenous clopidogrel

Medicago and PATH collaborate on broad-coverage flu vaccines

New HSP 90 inhibitors identified at sanofi-aventis

Bavarian Nordic receives grant to investigate Ebola and Marburg virus vaccines

MRC Technology describes new protein kinase inhibitors

Immunovaccine reports data on melioidosis vaccine candidate

European orphan drug status for NeuroSTAT in traumatic brain injury

Snapshots: Preclinical and early clinical development of GSK-1322322

PAION and Lundbeck expand desmoteplase license agreement

Merck & Co. claims new calcitonin CGRP receptor antagonists

Trophos begins efficacy trial of olesoxime in spinal muscular atrophy

Incyte discloses new histamine H4 receptor antagonists

Pfizer presents new GPR119 receptor agonists

Omeros receives additional grant from NIDA for addiction program

Taisho Toyama and Mitsubishi Tanabe launch 1000-mg pazufloxacin formulations

PharmaGap reports initial preclinical toxicity data on GAP-107B8

FibroGen begins phase II study of FG-3019 in liver fibrosis

University of Pittsburgh testing rectal use of tenofovir HIV prevention gel

NuPathe completes three trials to support NDA for Zelrix transdermal patch for migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...